Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

Phase 1

Completed

• Conditions: Healthy Subjects
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: PeakATP 250; Dietary Supplement: PeakATP 400; Dietary Supplement: PeakATP 400 plus proprietary blend

• Registration Number: NCT01141504
• Lead Sponsor: Metabolic Technologies Inc.

Brief Summary

Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

Detailed Description

To date we have studied 10 subjects who have followed through with all 3 of the original interventions (Placebo, 250 mg PeakATP/d and 400 mg PeakATP/d). Currently we have received approval and are expanding the study with 5 additional subjects who will receive the Placebo, 400 mg PeakATP/d and the 400 mg PealATP/d plus proprietary blend interventions.

Study Timeline

• Study Start: 2010-06
• Study First Submitted: 2010-06-09
• Study First Submitted QC: 2010-06-09
• Study First Posted: 2010-06-10
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-09
• Last Update Posted: 2012-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• No major medical conditions;
• Able to perform fatigue testing procedures;
• Not currently taking prescription medications;
• Not currently taking dietary supplements (a daily multi-vitamin not exceeding RDA is permitted)

Exclusion Criteria

• Major medical condition affecting metabolism or general function;
• Not able to perform fatigue testing;
• Taking prescription medications;
• Taking a dietary supplement other than a multi-vitamin not exceeding RDA

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Oral placebo capsules similar in color and size to the intervention
PeakATP 250	PeakATP 250	Oral supplement capsules containing 250 mg/day of PeakATP
PeakATP 400	PeakATP 400	Oral supplement capsules containing 400 mg/day of PeakATP
PeakATP 400 plus proprietary blend	PeakATP 400 plus proprietary blend	Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend

Primary Outcome Measures

Name	Time	Method
Work Performed	Measured after 15 days of intervention	The work and total work performed in 3 exercise fatigue tests given after 15 days of nutritional intervention.

Secondary Outcome Measures

Name	Time	Method
Decrease in work performed in each successive test	Measured after 15 days of intervention	The decrease in total work performed in each of 3 successive fatigue tests will be measured and used as a measure of muscle fatigability after 15 days of nutritional intervention

Trial Locations

Locations (1)

Iowa State University; 🇺🇸 Ames, Iowa, United States